SEBI Reg. Investment Advisor

Download App
Help Center Pricing
Money Works 4 Me Logo MoneyWorks4Me
Login Get Free Account
Sign Up

MoneyWorks4Me

Log In Sign Up Schedule Free 15‑min Call
Login Get Free Account
Sign Up

INVESTMENT INSIGHTS

Check Before You Invest : ANG Lifesciences India Ltd

BSE: 540694 NSE: ISIN: INE236W01016
  |   Sector:  Healthcare   |   Industry:  Pharmaceuticals & Drugs

Snapshot

Q.1 Which industry/sub-sector does ANG Lifesciences India Ltd belong to?
ANG Lifesciences India Ltd belongs to the Healthcare sector, operating specifically within the Pharmaceuticals & Drugs segment.
Q.2 Is ANG Lifesciences India Ltd a good quality company?
ANG Lifesciences India Ltd is a quality company, based on a 10 year financial track record.
Q.3 Is ANG Lifesciences India Ltd undervalued or overvalued?
ANG Lifesciences India Ltd appears Somewhat Undervalued, as its key valuation ratios are below with their past averages.
Q.4 Is ANG Lifesciences India Ltd a good buy now?
ANG Lifesciences India Ltd is not a good buy now, based on weak price trend analysis suggesting prices may fall. However, you need to check its quality and valuation before making a decision

Performance Analysis

Q.1 Revenue growth of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd revenue growth is -31.6% for FY-2025 , which is below its 5 year CAGR of -6.7% , indicating slower growth.
Q.2 Gross Profit margin of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Gross profit margin which is the profit after deduction of direct costs, is -7.4% for FY-2025 , which is below its 5 year median of 5.1% , indicating decreasing margins.
Q.3 Operating Profit Margin of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Operating Profit Margin which is the profit after deduction of all operating costs, is -1.13% for FY-2025 , which is below its 5 year median of 7.35% indicating decreasing margins.
Q.4 Net Profit Margin of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Net Profit Margin is -11.5% for FY-2025 , is below with its 5 year median of -0.32%, indicating decreasing margins.
Current Level Historic Median
Gross Profit Margin -7.4 5.1
Operating Profit Margin -1.13 7.35
Net Profit Margin -11.5 -0.32
Q.5 Return on Asset of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Return on Asset is -4.87%, which is below its 5 year historical median of -0.25%, indicating deteriorated asset utilization efficiency.
Q.6 Return on Equity (ROE) of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Return on equity is -14.38% for FY-2025 , which is below its historical median of -0.78%, indicating the business is making worse use of its shareholders capital.
Q.7 Return on capital employed (ROCE) of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Return on capital employed is -3.96% for FY-2025 , which is below its estimated weighted average cost of capital(WACC) 14%, indicating value preservation.
Q.8 Cash conversion cycle of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Cash conversion cycle is 200 days, above its historical median of 98 days, indicating deteriorated working capital management. However, you need to compare this with its peers in the industry.
Current Level Historic Median
Asset Turnover 0.42 0.79
ROE -14.38 -0.78
ROCE -3.96 9.18
Cash Conversion Cycle 200 days 98 days
Q.9 Debt to Equity ratio of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Debt-to-Equity ratio is 1.01 , which is above with the industry average of 0.15 , indicating higher debt levels in the industry.
Q.10 Debt to cash flow from operations of ANG Lifesciences India Ltd?
ANG Lifesciences India Ltd Debt to cash flow from operations is -29.57 , which is at a unhealthy level.

Ownership & governance

Q.1 Promoter shareholding and pledge status of ANG Lifesciences India Ltd?
Promoters hold 70.60% of the ANG Lifesciences India Ltd, with 44.88% of their stake pledged, indicating high pledge risk.

Peer comparison (industry-wise, mcap)

Q.1 Revenue growth of ANG Lifesciences India Ltd vs industry peers?
ANG Lifesciences India Ltd revenue CAGR is -6.65% , compared to the industry median CAGR of 5.54% , indicating slower growth and losing its market share.
Profit Metrics
Current Level Industry Median
Revenue 89.9 137.1
Gross Profit -6.7 15.1
Operating Profit -1.5 16
Net Profit -10.3 5.6
Operating Efficiency
Current Level Industry Median
Asset Turnover 0.42 0.8
ROE -14.38 8.91
ROCE -3.96 11.59
Cash Conversion Cycle (days) 200.18 76

Valuation & price assessment

Q.1 Stock return of ANG Lifesciences India Ltd over the last decade?
Over the last 5 year(s), the stock has delivered a CAGR of -10.22% based on the current price.
Q.2 What return has the stock given over the last decade?
9Y 5Y 3Y 1Y
Share Price - -10.2% -33.4% -13.1%
Q.3 Valuation ratios of ANG Lifesciences India Ltd vs historical?
The current P/E is similar that its historical median.
Q.4 How do the current valuation ratios measure up against the historic numbers and the current industry numbers?
Valuation Ratios Current Historic Median Industry Median
Price to Earnings - 0.00 40.28
Price to Book 0.52 0.00 2.77
Price to Sales 0.37 0.00 2.65
EV to EBITDA 35.59 33.28 15.67

Check more companies

1. Ajanta Pharma
2. JB Chem & Pharma
3. Emcure Pharma
4. Gland Pharma
5. Wockhardt
6. Pfizer
7. Astrazeneca Pharma I
8. Sai Life Sciences
9. Natco Pharma
10. Eris Lifesciences
2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×